Company intelligence / Profile preview

Rong Wei

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Rongwei Biotech is a Shanghai-based biotechnology company specializing in the discovery and development of macrocyclic peptide therapeutics. The company utilizes a proprietary platform that combines DNA-encoded library (DEL) technology with macrocyclic peptide chemistry to identify high-affinity ligands for challenging biological targets. Their focus includes oncology and metabolic diseases, aiming to bridge the gap between small molecules and biologics. The company was founded by industry veterans with extensive experience in DEL and peptide drug discovery.

Therapeutic areas: ImmunologyMetabolic DisordersOncology
Modalities: Macrocyclic peptidesPeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Rong Wei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rong Wei.

Explore the full profile